Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

• Chien-Yu Lin,
• Sheng-Huan Wei,
• Yi-Lin Chen,
• Chung-Ta Lee,
• Shang-Yin Wu,
• Chung-Liang Ho,
• Dean C. Pavlick,
• Po-Lan Su,
• Chien-Chung Lin,
• Chien-Chung Lin,
• Chien-Chung Lin

Affiliations

Chien-Yu Lin

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Sheng-Huan Wei

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Yi-Lin Chen

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Chung-Ta Lee

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Shang-Yin Wu

Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Chung-Liang Ho

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Dean C. Pavlick

Department of Research and Development, Foundation Medicine, Inc., Cambridge, MA, United States

Po-Lan Su

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Chien-Chung Lin

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Chien-Chung Lin

Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Chien-Chung Lin

Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan